Neuphoria Therapeutics (NEUP) Revenue (2024 - 2025)

Neuphoria Therapeutics' (NEUP) quarterly Revenue came in at -$13267.0 in Q2 2025, down 100.09% quarter-over-quarter from $15.0 million in Q1 2025.

Analysis

Neuphoria Therapeutics (NEUP) Revenue (2024 - 2025) Analysis & Trends

Neuphoria Therapeutics (NEUP) has reported Revenue for 2 consecutive years, with -$13267.0 the latest figure, recorded in Q2 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	10.05 Bn
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	7.80 Bn
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	3.33 Bn
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	4.29 Bn
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	1.52 Bn
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	145.00 Mn
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	1.29 Bn
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	2.74 Bn
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	1.44 Mn
10	Neuphoria Therapeutics	463.74 Mn	444.30 Mn	-	-

Historic Data

Download Data